Analysts Issue Forecasts for Cingulate Q1 Earnings

Cingulate Inc. (NASDAQ:CING) – Research analysts at Ascendiant Capital Markets lifted their Q1 2026 earnings per share estimates for Cingulate in a report issued on Tuesday, April 7th. Ascendiant Capital Markets analyst E. Woo now expects that the company will earn ($0.38) per share for the quarter, up from their prior forecast of ($0.64). Ascendiant Capital Markets has a “Buy” rating and a $55.00 price target on the stock. The consensus estimate for Cingulate’s current full-year earnings is ($11.69) per share. Ascendiant Capital Markets also issued estimates for Cingulate’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.52) EPS and Q4 2027 earnings at ($0.32) EPS.

Several other equities research analysts have also commented on CING. Roth Mkm cut their price target on shares of Cingulate from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cingulate in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $34.50.

Cingulate Trading Down 2.8%

Shares of Cingulate stock opened at $5.20 on Wednesday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.46. The company has a fifty day simple moving average of $6.73 and a 200-day simple moving average of $5.12. The stock has a market cap of $60.47 million, a price-to-earnings ratio of -1.20 and a beta of -0.76. Cingulate has a 12-month low of $3.20 and a 12-month high of $11.89.

Cingulate (NASDAQ:CING) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.28).

Institutional Trading of Cingulate

A number of large investors have recently bought and sold shares of the business. DRW Securities LLC acquired a new stake in shares of Cingulate during the fourth quarter worth about $255,000. Kestra Advisory Services LLC increased its position in Cingulate by 29.8% in the 4th quarter. Kestra Advisory Services LLC now owns 122,000 shares of the company’s stock valued at $529,000 after acquiring an additional 27,979 shares during the period. XTX Topco Ltd acquired a new position in Cingulate in the 4th quarter valued at about $90,000. Geode Capital Management LLC raised its stake in Cingulate by 43.9% during the 4th quarter. Geode Capital Management LLC now owns 61,035 shares of the company’s stock valued at $265,000 after acquiring an additional 18,629 shares during the last quarter. Finally, Quadrature Capital Ltd purchased a new stake in Cingulate during the 4th quarter valued at approximately $66,000. Institutional investors and hedge funds own 41.31% of the company’s stock.

Insider Activity at Cingulate

In other Cingulate news, Director Peter J. Werth bought 19,455 shares of the business’s stock in a transaction dated Friday, February 6th. The shares were acquired at an average cost of $5.04 per share, with a total value of $98,053.20. Following the acquisition, the director directly owned 117,449 shares of the company’s stock, valued at $591,942.96. The trade was a 19.85% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Shane J. Schaffer bought 6,809 shares of the business’s stock in a transaction dated Friday, February 6th. The stock was acquired at an average cost of $5.04 per share, for a total transaction of $34,317.36. Following the completion of the acquisition, the chief executive officer directly owned 10,175 shares in the company, valued at approximately $51,282. This trade represents a 202.29% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought 33,074 shares of company stock valued at $166,693 over the last three months. Corporate insiders own 4.33% of the company’s stock.

Key Headlines Impacting Cingulate

Here are the key news stories impacting Cingulate this week:

• Positive Sentiment: Ascendiant boosted 2026 quarterly EPS forecasts across Q1–Q4 to ($0.38) from prior larger losses (previously ~($0.63)–($0.64)) and raised FY2026 to ($1.52) from ($2.54), signaling faster-than-expected improvement. Ascendiant also reiterates a “Buy” rating with a $55 price target. MarketBeat: Ascendiant Estimates
• Positive Sentiment: Ascendiant refreshed multi‑quarter/annual estimates for 2027 (Q1–Q3/ FY2027) showing moderating losses (example: FY2027 ~($1.39) and Q4 2027 ~($0.32)), which supports a narrative of gradual recovery over 2026–27. MarketBeat: Ascendiant 2027 Estimates
• Neutral Sentiment: The analyst revisions reflect model changes rather than an announced operational catalyst (no new guidance or product/partnership news disclosed), so market reaction depends on conviction in management execution and upcoming results. MarketBeat: Analyst Note
• Negative Sentiment: Cingulate reported a Q1 (Mar 18) EPS miss—($0.84) vs. ($0.56) expected—which remains a near-term headwind and likely explains some selling pressure despite the analyst upgrades. MarketBeat: Earnings Miss
• Negative Sentiment: Broader consensus still expects large full‑year losses (consensus cited ~($11.69) EPS), and technicals show the stock below its 50‑day average — factors that can limit upside until results and cash/burn outlook improve. MarketBeat: Consensus Data

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.